(Q35552612)

8 August 2017

1 reference

title

PET scans in the staging of lymphoma: current status (English)

1 reference

8 August 2017

PET Scans in the Staging of Lymphoma: Current Status (English)

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

18 March 2024

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

18 March 2024

author name string

Vaseem Chengazi

2

1 reference

8 August 2017

Jonathan W. Friedberg

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14530496

18 March 2024

language of work or name

1 reference

1 January 2003

1 reference

full work available at URL

8 August 2017

https://academic.oup.com/oncolo/article-pdf/8/5/438/41840492/oncolo_8_5_438.pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14530496

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.8-5-438

18 March 2024

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

https://onlinelibrary.wiley.com/doi/full-xml/10.1634/theoncologist.8-5-438

18 March 2024

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

https://academic.oup.com/oncolo/article-pdf/8/5/438/41840492/oncolo_8_5_438.pdf

18 March 2024

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

18 March 2024

1 reference

8 August 2017

8

1 reference

8 August 2017

5

1 reference

8 August 2017

438-447

1 reference

Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors

8 August 2017

1

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

Decision analysis on alternative treatment strategies for favorable-prognosis, early-stage Hodgkin's disease

18 March 2024

2

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

Pre- and post-treatment evaluation of non-Hodgkin's lymphoma

18 March 2024

3

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy

18 March 2024

4

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

The gallium scan predicts relapse in patients with Hodgkin's disease treated with combined modality therapy

18 March 2024

5

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

Gallium scans in the management of patients with Hodgkin's disease: a study of 101 patients

18 March 2024

6

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

The role of Ga-67 scintigraphy in evaluating the results of therapy of lymphoma patients

18 March 2024

7

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears?

18 March 2024

8

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

Impact of fluorine-18 fluorodeoxyglucose positron emission tomography on patient management: first year's experience in a clinical center

18 March 2024

9

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

[18F]-FDG positron imaging in clinical management of lymphoma patients.

18 March 2024

10

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

Prognostic Significance of 18 F-fluorodeoxyglucose Positron Emission Tomography in Lymphoma

18 March 2024

11

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

Utility of FDG-PET scanning in lymphoma by WHO classification

18 March 2024

12

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type

18 March 2024

13

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma

18 March 2024

14

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL).

18 March 2024

15

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL).

18 March 2024

16

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

Predicting malignancy grade with PET in non-Hodgkin's lymphoma

18 March 2024

17

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity

18 March 2024

18

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

The impact of FDG positron emission tomography imaging on the management of lymphomas

18 March 2024

20

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution

18 March 2024

21

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease

18 March 2024

22

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma

18 March 2024

23

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma

18 March 2024

24

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

Positron emission tomography in lymphoma: comparison with computed tomography and Gallium-67 single photon emission computed tomography

18 March 2024

29

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging

18 March 2024

30

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest

18 March 2024

31

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

Fluorine-18 fluorodeoxyglucose positron emission tomography for lymphoma: incorporating new technology into clinical care

18 March 2024

32

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

Primary staging of lymphomas: cost-effectiveness of FDG-PET versus computed tomography

18 March 2024

33

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose

18 March 2024

34

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma

18 March 2024

38

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?

18 March 2024

39

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT

18 March 2024

40

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses?

18 March 2024

41

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

The role of positron emission tomography (PET) in the management of lymphoma patients

18 March 2024

42

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease

18 March 2024

43

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease.

18 March 2024

44

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

Role of attenuation correction for fluorine-18 fluorodeoxyglucose positron emission tomography in the primary staging of malignant lymphoma

18 March 2024

45

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease

18 March 2024

46

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma

18 March 2024

47

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

Staging and monitoring response to treatment in primary non-Hodgkin's lymphoma of bone marrow using (18)F-fluorodeoxyglucose positron emission tomography

18 March 2024

48

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

Extranodal malignant lymphoma: detection with FDG PET versus CT

18 March 2024

49

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow

18 March 2024

50

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

Granulocyte colony-stimulating factor: confounding F-18 FDG uptake in outpatient positron emission tomographic facilities for patients receiving ongoing treatment of lymphoma

18 March 2024

52

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

Positron emission tomography in patients with primary CNS lymphomas

18 March 2024

53

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

F-18 FDG versus Ga-67 for detecting splenic involvement in Hodgkin's disease

18 March 2024

54

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation

18 March 2024

55

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation

18 March 2024

56

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma

18 March 2024

58

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

The impact of external beam radiation therapy prior to autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma

18 March 2024

59

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

Assessment of tumor burden and treatment response by 18F-fluorodeoxyglucose injection and positron emission tomography in patients with cutaneous T- and B-cell lymphomas

18 March 2024

60

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) for assessment of enteropathy-type T cell lymphoma

18 March 2024

61

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

18F-Fluorodeoxyglucose PET in a patient with primary small bowel lymphoma: the only sensitive method of imaging

18 March 2024

62

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma

18 March 2024

63

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

[(18)F]FDG in childhood lymphoma: clinical utility and impact on management

18 March 2024

64

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease

18 March 2024

67

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma

18 March 2024

68

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-438

18 March 2024

Identifiers

1 reference

8 August 2017

1 reference